Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

BACKGROUND: The identification of molecular and genetic markers to predict or monitor the efficacy of bevacizumab (BV) represents a key issue in the treatment of metastatic colorectal cancer (mCRC). METHODS: Plasma levels of vascular endothelial growth factor (VEGF), placental growth factor (PlGF),...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Loupakis, F, Cremolini, C, Fioravanti, A, Orlandi, P, Salvatore, L, Masi, G, Di Desidero, T, Canu, B, Schirripa, M, Frumento, P, Di Paolo, A, Danesi, R, Falcone, A, Bocci, G
格式: Artigo
語言:Inglês
出版: Nature Publishing Group 2011
主題:
Clinical Study
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC3078596/
https://ncbi.nlm.nih.gov/pubmed/21407216
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.85
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍